ReviewJournal of medical virology2020
Controversial treatments: An updated understanding of the coronavirus disease 2019.
Review in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.British journal of clinical pharmacology · 2022Pooled it
- A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.Life sciences · 2020Pooled it
- Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.The western journal of emergency medicine · 2020Pooled it
- Article
- Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021.International journal of environmental research and public health · 2022Review
- New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach.Molecular diversity · 2022Article
- Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models.Viruses · 2022Article
- Fragment-based in silico design of SARS-CoV-2 main protease inhibitors.Chemical biology & drug design · 2021Article
- CROssBAR: comprehensive resource of biomedical relations with knowledge graph representations.Nucleic acids research · 2021Article
- Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.World journal of clinical cases · 2021Article
- Efficiency of Prolonged Prone Positioning for Mechanically Ventilated Patients Infected with COVID-19.Journal of clinical medicine · 2021Article
- Ultraefficiently Calming Cytokine Storm Using TiSmall methods · 2021Article
- A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR.EClinicalMedicine · 2021Article
- Covalent Antiviral Agents.Advances in experimental medicine and biology · 2021Review
- Longitudinal Characterization of Cytokine Overproduction: A Case Report in Critically Ill COVID-19 Patients With Hyperinflammation in Bronchoalveolar Lavage.Frontiers in medicine · 2021Article
- Impact of repurposed drugs on the symptomatic COVID-19 patients.Journal of infection and public health · 2021Review
- Statistical data driven approach of COVID-19 in Ecuador:Infectious Disease Modelling · 2021Article
- Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.Journal of medical virology · 2021Article
- Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study.Journal of global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An outbreak of severe acute respiratory syndrome-related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.